Global Head of Biologics Jayanth Sridhar resigns, effective 31 Jan 2026

Kmp ResignedManagement Changes View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.2%Reaction day

₹1198.50

prior close

₹1203.60

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.4%+0.8% vs market

Pharmaceuticals peers, median of 157sector-0.2%+1.4% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty 100 and 1.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.4

15m

-0.2

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.2+0.4+0.8-0.2+1.4

Next day

+2.7+1.0+1.6+0.5+2.2

+3.0+1.0+1.9+0.6+2.4

+4.0+1.1+2.9+0.3+3.7

+3.8+1.6+2.2+0.2+3.6

+3.6+1.1+2.5-0.6+4.3

+4.1+2.0+2.1-1.1+5.2

15d

+6.5+1.4+5.1-2.1+8.6

+6.4+0.7+5.7-3.2+9.6

+1.5+0.5+1.0-5.9+7.4

+5.7+1.4+4.3-6.4+12.1

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr. Reddy's Laboratories has informed exchanges that Mr. Jayanth Sridhar, Global Head of Biologics, has resigned to pursue aspirations outside the company. He will cease employment and Senior Management Personnel role from the close of business on January 31, 2026. He will stay available until January 2026 for smooth transition. The resignation letter is attached.

Likely market impact

Loss of a senior leader in the Biologics business; transition period until end of Jan 2026 should limit immediate disruption, but investor focus now shifts to succession plan.